Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : BJCT-BIOJECT-needle less injection product -- Ignore unavailable to you. Want to Upgrade?

To: Marc Kahn who wrote (81)	11/17/1997 2:52:00 PM
From: Michael C. Woodward	Read Replies (1) \| Respond to of 534

Good input on BJCT. After special stockholders meeting, scheduled for Dec 9th, I see the following positives for next year, assuming that their proposals are approved by the stockholders: 1. Joint venture with Elan on glucose monitoring for diabetics gets started. 2. Conversion of promissory note with Elan for $12 million for convertible preferred stock. Will give them improved cash flow. 3. 38% of stock held by three investors (1) Elan Int'l (16.6%), (2) Hambrecht & Quist (12.8%) and Paramont Capital (8.4%). 4. Base business looks solid.

To: Marc Kahn who wrote (81)	11/19/1997 6:58:00 AM
From: geewiz	Read Replies (1) \| Respond to of 534

Marc, Thanks for posting the numbers. I was disappointed in the flue season revenue. I get the impression that management was also; "turnout was spotty". Any news from Redmond on what vaccines the company is targeting? It's my guess that it will be easier to sell our delivery system to an agency or clinic giving one vacinne. art

To: Marc Kahn who wrote (81)	12/21/1997 1:39:00 PM
From: geewiz	Read Replies (2) \| Respond to of 534

Hello all, I profess suprise and confusion on BJCT's announced glucose monitoring market direction. Two years ago I asked if the company's injectors could be used for the insulin market and I was told they lacked sufficient capactiy. Then DeWeese joined the board. He brings a lot of experience in this market segment through his background at Cygnus. The purchased technologhy from Elan is also significant. Yet my perception of the field is that it is one of the more hyped and competitive markets in the medical delivery field (not that BJCT is suffering from this affliction). This is due to the great opportunities that await any company that can make glucose monitoring and insulin delivery easier and less painful. There is a Minnesota company I've been following for several years that appears to be making progress but I have no idea how their technology platform compares with ours; biz.yahoo.com If I get some time over the holidays I will make an effort to collate and post a summary of these companys. I'd be greatful for any imput on this technology, of which I know nothing. Happy Holidays, art